Prescription Drug Supply Chain Pricing Transparency Act

The Prescription Drug Supply Chain Pricing Transparency Act requires the Government Accountability Office (GAO) to study how compensation and payment structures affect prescription drug prices within the supply chain. The GAO will examine how intermediaries like pharmacy benefit managers, drug wholesalers, and manufacturers set fees based on drug prices - including potential conflicts of interest - and analyze trends over time. This study must be completed within two years, with findings and recommendations submitted to Congress. The bill does not change current laws but aims to increase transparency for future policy decisions.